Hormonal
Elevated baseline plasma copeptin levels independently predict the future development of type 2 diabetes and abdominal obesity, suggesting a primary role for the vasopressin system in cardiometabolic risk.
High copeptin levels, a marker of vasopressin activity, are associated with a higher risk of developing type 2 diabetes and abdominal obesity over the long term. While copeptin itself is not a treatment target, its elevation signals a dysregulated system. Focus on maintaining a healthy waist circumference and blood sugar levels through diet and exercise, as these factors influence the vasopressin system and reduce cardiometabolic risk.
The key finding of this study is that an elevated copeptin at baseline predicts incident DM, abdominal obesity and microalbuminuria during a long-term follow-up (15.8 years on average).
Why this rating
Large prospective cohort (n=2064), long follow-up (15.8 years), rigorous adjustment for confounders, but observational design limits causal inference.
Source
Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmö Diet and Cancer Study cardiovascular cohort
Sofia Enhörning et al. · International Journal of Obesity · 2012
DOI 10.1038/ijo.2012.88
More from this paper
- Elevated baseline plasma copeptin levels independently predict the future development of microalbuminuria, even after adjusting for incident diabetes and hypertension.Good
- Elevated baseline plasma copeptin levels do NOT independently predict the development of the full metabolic syndrome cluster, despite predicting its individual components (DM and abdominal obesity).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →